BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker
BCL2-family proteins have a central role in the mitochondrial apoptosis machinery and their expression is known to be deregulated in many cancer types. Effort in the development of small molecules that selectively target anti-apoptotic members of this family i.e., Bcl-2, Bcl-xL, Mcl-1 recently opene...
Main Authors: | Benoît Tessoulin, Antonin Papin, Patricia Gomez-Bougie, Celine Bellanger, Martine Amiot, Catherine Pellat-Deceunynck, David Chiron |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00645/full |
Similar Items
-
BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival
by: Ophélie Champion, et al.
Published: (2023-07-01) -
Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
by: Maxime Jullien, et al.
Published: (2020-03-01) -
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
by: Diana Malarikova, et al.
Published: (2024-03-01) -
Roles and Regulation of BCL-xL in Hematological Malignancies
by: Mario Morales-Martínez, et al.
Published: (2022-02-01) -
Bcl-2 Immunoexpression in Feline Epitheliotropic Intestinal T-Cell Lymphomas
by: Agustín Rebollada-Merino, et al.
Published: (2022-03-01)